Summary:
Coronary Artery Disease (CAD) and Congestive Heart Failure (CHF) affect millions of people around the world each year. While standard treatment can help most, the rest continue to go untreated with little or no hope. VesCell uses a patient’s own adult stem cells to treat these debilitating diseases and is a viable alternative for patients who either cannot undergo or choose not to undergo the standard treatment such as Coronary Artery Bypass Grafting (CABG).
Visit Theravitae Co., Ltd.: VesCell.

Description (Web site quote):
VesCell is a product of Theravitae Co., Ltd., an international biotechnology company. VesCell utilizes patients' own cells to treat cardiovascular diseases. The company consists of three operating centers. The clinical development and marketing center is located in Bangkok, Thailand. It is responsible, in cooperation with local partner hospitals, for conducting clinical trials and providing VesCell therapy to patients world-wide. The state-of-the-art research, development and manufacturing center in Kiryat Weizmann, Israel produces VesCell and conducts ongoing research and development for all TheraVitae products. All finance-related issues are handled by the Hong Kong finance center. The company benefits from collaborations with eminent physicians and scientists who are affiliated with renowned medical and academic institutions.

VesCell is a cellular-based product that is used to treat patients who suffer from chest pain or discomfort (Angina Pectoris) caused by the blockage of vessels that bring oxygen- and nutrient-carrying blood to the heart. VesCell helps promotes the formation of natural bypass blood vessels, thus alleviating the clinical condition of patients. VesCell is also used to treat ischemic heart disease patients who have exhausted other treatment options such as coronary artery bypass grafting (CABG) or who do not wish to undergo CABG.
Visit Theravitae Co., Ltd.: VesCell.